TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible

ORLANDO, Fla. and DUBLIN, Sept. 23, 2014 /PRNewswire/ --TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the "Company"), a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced that the Depository Trust Company ("DTC") has approved our common stock for DTC's Deposit and Withdrawal at Custodian ("DWAC") service using a Fast Automated Securities Transfer Service ("FAST") transfer agent as the distribution point.  The Company's shareholders holding their securities in street name can now transfer their shares electronically after buying or selling on the open market without the extra expense and delay resulting from the redundant process of requesting and transferring physical certificates.

Benefits to our shareholders as a result of becoming DWAC/FAST approved include reducing the time from weeks to hours for stock deposits and withdrawals into brokerage accounts while eliminating the inherent risks associated with the loss and replacement of physical stock certificates.

The Company's CEO, Noreen Griffin, stated "We are pleased to share this corporate development with our shareholders. DTC worked with us to make the Company DWAC/FAST eligible therefore obviating the mandatory surrender of our share certificates for street name shareholders to receive the Cytocom Inc. share dividend."  We thank DTC for making this possible for our shareholders.

Our shareholders will receive one common share of Cytocom Inc. for every one share of our common stock held by such shareholders as of 5:00 p.m., Eastern Time, on September 30, 2014, which is the "record date" for the share distribution.

Shareholders who hold our shares in street name do not need to take any action to receive the Cytocom Inc. share dividend.  This will be done with their broker communicating beneficial owner information directly to our transfer agent.

After the Financial Industry Regulatory Authority declares the payable date for the Cytocom Inc. share distribution, our transfer agent will send to each shareholder proof of Cytocom Inc. common stock ownership, as of the record date. Cytocom Inc. shares will be kept in book entry.

If our transfer agent is holding certificates for shareholders in connection with the Cytocom Inc. share dividend, such certificates will be returned to the shareholder after the record date.

If you have any questions regarding the Cytocom Inc. share dividend, please contact our transfer agent Guardian Registrar & Transfer, Inc. to address your questions at 7951 SW 6th Street, Suite 216, Plantation, FL 33324, (877) 797-3632, [email protected], or contact our General Counsel, Kirsten Bartholomew, at [email protected].

Cautionary Note Regarding Forward-Looking Statements

This document includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the plans, objectives, expectations and intentions of the Company, including the benefits of the proposed spin-off of Cytocom Inc. from the Company, and other statements that are not historical facts. These statements are based on the current expectations and beliefs of our management and are subject to uncertainty and changes in circumstances. We caution readers that any forward-looking information is not a guarantee of future performance and that actual results may vary materially from those expressed or implied by the statements herein due to the conditions to the consummation of the proposed spin-off of Cytocom Inc. from the Company, and changes in economic, business, competitive, technological, strategic and/or regulatory factors, as well as other factors affecting the operation of the other businesses of the Company and Cytocom Inc.. More detailed information about these factors may be found in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K in the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors." Various other factors could cause actual results to differ from those set forth in the forward-looking statements, including, without limitation, the risk that the anticipated benefits from the proposed spin-off may not be fully realized or may take longer to realize than expected. We are under no obligation to, and expressly disclaim any such obligation to, update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

About TNI BioTech, Inc.

TNI BioTech, Inc. is a biopharmaceutical company involved in manufacturing, distribution, and marketing of our rights to our immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system in fighting chronic and life threatening diseases. Our goal is to provide affordable sustainable health care in emerging nations where little or no treatments exist for many of these diseases.

Our therapies have been shown in clinical trials to stimulate the immune system in patients with cancer, autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, fibromyalgia, melanoma, prostate cancer, cervical cancer, and inflammatory bowel disease. The therapies may be used as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery and in combination with antibiotics or retroviral drug therapy in the treatment of a variety of infectious diseases, including patients with HIV/AIDS.

About Cytocom, Inc.

Cytocom Inc. is a biotechnology company that will initially focus on developing Low Dose Naltrexone and Methionine [Met5]-enkephalin in the investigation of unmet medical needs in the areas of oncological and inflammatory diseases.

Contact: 
Dennis S. Dobson 
203-258-0159

SOURCE TNI BioTech, Inc.